Compare Stocks → Move Your Money Before May 22 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYCNNASDAQ:LABPNASDAQ:NRSNNASDAQ:ONCSNASDAQ:ONTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$2.93-3.6%$3.10$1.75▼$6.75$7.94M1.843,135 shs276 shsLABPLandos Biopharma$22.31-0.8%$13.74$2.50▼$22.84$69.61M0.1421,743 shs14,876 shsNRSNNeuroSense Therapeutics$1.24-1.6%$1.65$0.40▼$2.33$16.95M1.58273,337 shs41,868 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsONTXOnconova Therapeutics$0.84$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+10.95%-2.43%+1.29%+7.17%-44.83%LABPLandos Biopharma-0.04%+2.71%+3.66%+384.82%+645.00%NRSNNeuroSense Therapeutics-5.97%-17.11%-25.88%+23.53%-37.31%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-68.50%ONTXOnconova Therapeutics0.00%0.00%+10.59%+40.84%-5.21%The Next Step of Their Control Is Here … (Ad)Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALABPLandos Biopharma0.7503 of 5 stars1.05.00.00.03.30.80.6NRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/AONTXOnconova Therapeutics0.7728 of 5 stars3.53.00.00.00.00.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion TherapeuticsN/AN/AN/AN/ALABPLandos Biopharma2.00Hold$20.42-8.47% DownsideNRSNNeuroSense Therapeutics3.00BuyN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideCurrent Analyst RatingsLatest ONTX, LABP, CYCN, NRSN, and ONCS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024LABPLandos BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$50.00 ➝ $20.42(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$1.62M4.90N/AN/A$4.62 per share0.63LABPLandos Biopharma$18M3.87N/AN/A$10.20 per share2.19NRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.14) per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$5.26M-$5.51N/A∞N/AN/A-111.79%-74.10%5/9/2024 (Estimated)LABPLandos Biopharma-$21.93M-$3.46N/AN/AN/AN/A-54.92%-49.09%5/10/2024 (Estimated)NRSNNeuroSense Therapeutics-$11.28M-$0.83N/A∞N/AN/A-678.59%-207.30%6/6/2024 (Estimated)ONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/AONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)Latest ONTX, LABP, CYCN, NRSN, and ONCS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/5/2024Q4 2023NRSNNeuroSense TherapeuticsN/A-$0.16-$0.16-$0.16N/AN/A3/21/2024Q4 2023LABPLandos Biopharma-$0.91-$0.99-$0.08-$0.99N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A3.853.85LABPLandos BiopharmaN/A6.096.09NRSNNeuroSense TherapeuticsN/A0.840.84ONCSOncoSec MedicalN/A0.890.89ONTXOnconova TherapeuticsN/A2.792.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%LABPLandos Biopharma49.06%NRSNNeuroSense Therapeutics1.04%ONCSOncoSec Medical8.69%ONTXOnconova Therapeutics7.95%Insider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics13.10%LABPLandos Biopharma1.30%NRSNNeuroSense Therapeutics27.40%ONCSOncoSec Medical1.32%ONTXOnconova Therapeutics3.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics12.71 million2.36 millionNo DataLABPLandos Biopharma193.12 million3.08 millionNot OptionableNRSNNeuroSense Therapeutics1413.67 million9.92 millionNot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableONTX, LABP, CYCN, NRSN, and ONCS HeadlinesSourceHeadlineOnconova Therapeutics (NASDAQ:ONTX) Now Covered by StockNews.comamericanbankingnews.com - April 24 at 2:22 AMOnconova Therapeutics (NASDAQ:ONTX) Coverage Initiated at StockNews.comamericanbankingnews.com - April 16 at 2:22 AMOnconova and Trawsfynydd merge to form Traws Pharmauk.investing.com - April 4 at 6:50 PMTraws Pharma Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - April 4 at 6:50 PMNewtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with Trawsfynyddmsn.com - April 3 at 5:47 PMOnconova Acquires Trawsfynydd To Form Traws Pharmamarkets.businessinsider.com - April 2 at 10:00 AMTraws Pharma Announces New Employee Inducement Grantsglobenewswire.com - April 2 at 7:15 AMOnconova to Unveil New Rigosertib Study Results at Cancer Research Meetingmsn.com - March 12 at 8:48 AMAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)markets.businessinsider.com - March 11 at 1:17 PMOnconova Therapeutics’ Rigosertib Poster Selected for AACR 2024finance.yahoo.com - March 8 at 9:56 AMOnconova Therapeutics' Rigosertib Poster Selected for AACR 2024globenewswire.com - March 8 at 8:00 AMOnconova Therapeutics Inc (ONTX)investing.com - February 13 at 12:22 AMOnconova Therapeutics, Inc. (ONTX)finance.yahoo.com - January 23 at 10:41 PMOnconova Therapeutics Stock (NASDAQ:ONTX) Dividends: History, Yield and Datesbenzinga.com - December 21 at 11:07 PMOnconova stock falls 10% on preclinical data for lymphoma drugmsn.com - December 12 at 4:02 PMOnconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphomafinance.yahoo.com - December 12 at 9:55 AMOnconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’sfinance.yahoo.com - December 8 at 6:47 PMOnconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conferencefinance.yahoo.com - November 28 at 10:06 AMOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 16 at 12:48 PMOnconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Resultsfinanznachrichten.de - November 16 at 1:30 AMOnconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 14 at 6:28 PMOnconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023finance.yahoo.com - November 7 at 5:22 PMOnconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCLbenzinga.com - November 2 at 7:56 PMOnconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCLfinance.yahoo.com - November 2 at 2:55 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCyclerion TherapeuticsNASDAQ:CYCNCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Landos BiopharmaNASDAQ:LABPLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.NeuroSense TherapeuticsNASDAQ:NRSNNeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.